Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascletis's IND Filing for Third HCV Treatment Accepted in China

publication date: Jan 3, 2019

Ascletis Pharma of Hangzhou reported that China's NMPA accepted its filing for an investigational new drug application (IND) of its third HCV drug, ASC21. Ascletis said ASC21 has shown potent, pan-genotypic anti-viral activity along with a high genetic barrier to resistance in in vitro studies. In mid-2018, Ascletis launched Ganovo^® in China, the company's first approved innovative HCV treatment. Its second candidate, Ravidasvir, is currently under review by the NMPA. Because each of the three drugs has a different mechanism of action, Ascletis believes it will offer treatment for all varieties of HCV. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.